Review argues fixed-dose radiopharmaceutical therapy may underdose many patients

This review examines whether current radiopharmaceutical therapies such as Lu-vipivotide tetraxetan and Lu-DOTATATE, which use a one-administered-activity-fits-all approach without patient dosimetry, adequately account for patient-to-patient variability. The authors report that state-of-the-art dosimetry data show heterogeneity in absorbed dose to tumors and organs, suggesting a significant number of patients are underdosed relative to organ tolerance, and present data suggesting improved outcomes when dosimetry is used to plan treatment. The article proposes greater collection of dosimetry data, including through a nascent National Oncologic Dosimentry Registry, to support dose optimization, combination with external beam radiotherapy, and better understanding of RPT safety and tolerability.

Most relevant for: Patients receiving Lu-DOTATATE or Lu-vipivotide tetraxetan radiopharmaceutical therapy for neuroendocrine tumors or prostate cancer.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.